What Is PJP Pneumonia and Who Is Most at Risk?

Pneumocystis jirovecii pneumonia, usually called PJP or sometimes PCP, is a lung infection caused by a fungus that almost exclusively strikes people with weakened immune systems. It was one of the defining illnesses of the early AIDS epidemic, and while antiretroviral therapy has dramatically reduced its frequency in people living with HIV, PJP has increasingly shown up in other immunocompromised populations, from organ transplant recipients to patients on long-term immunosuppressive drugs. The organism behind it, Pneumocystis jirovecii, is unusual among fungi: it cannot be grown reliably in a lab dish, spreads through the air, and quietly colonizes the lungs of healthy people without ever making them sick.

What the Organism Actually Does in Your Lungs

Pneumocystis jirovecii has two main life stages in the lung. The feeding forms, called trophic forms, latch onto the thin cells lining the air sacs where gas exchange happens. These trophic forms preferentially anchor to type I alveolar epithelial cells, attaching through a complex infolding between their pseudopod-like structures and the host cell membrane without actually breaking through the cell’s surface.¹ The binding is dose-dependent and involves fibronectin, a sticky protein on cell surfaces, along with specific receptor molecules called integrins.² As the organisms multiply, they fill the air sacs with a foamy, protein-rich material that blocks oxygen from crossing into the bloodstream. That is why the hallmark symptom is progressive shortness of breath rather than the productive cough you get with bacterial pneumonia.

The damage, though, is not purely the fungus’s doing. Much of the lung injury comes from the immune response itself. In animal models, a specific subset of immune cells called regulatory T cells acts as a brake on inflammation during Pneumocystis infection. When those regulatory cells are absent or depleted, inflammatory signaling ramps up dramatically and lung injury worsens, even when the fungal burden stays the same.³ This helps explain a paradox clinicians see regularly: patients whose immune systems partially recover while infected can actually get sicker before they get better, because the returning immune cells generate inflammation the lungs were not experiencing before.

How It Spreads and Who Carries It

The main transmission route is airborne. The infectious form is thought to be the cyst stage, which can survive in the air after being exhaled. Researchers have detected P. jirovecii DNA in the air around infected patients up to eight meters away from their beds, including in hospital corridors.⁴ It is not just actively sick patients who shed the organism. People who are colonized without symptoms also exhale detectable Pneumocystis DNA, and genotyping has confirmed that the strains in the surrounding air match the strains in those patients’ lungs.⁵

Colonization itself is remarkably common. The organism has been found in respiratory samples from people who have no symptoms at all, with colonization rates ranging widely depending on the population: anywhere from undetectable to over 60% in some immunocompetent groups, around 15% in pregnant women, 20 to 69% in HIV-positive individuals, and 16 to 55% in people with chronic obstructive pulmonary disease.⁶ Pneumocystis DNA has even been recovered from filtered hospital air samples, and patients receiving corticosteroids in intensive care were colonized at higher rates, raising questions about nosocomial spread.⁷ The practical upshot is that most of us encounter this fungus during our lives, but a healthy immune system clears or suppresses it before it causes trouble.

Who Is at Risk, and Why HIV Status Changes the Picture

The classic at-risk group is people with advanced HIV whose CD4 cell counts have dropped below 200 cells per cubic millimeter. But PJP is no longer predominantly an HIV disease in many hospitals. In a large French study, the majority of PJP cases were already occurring in HIV-negative patients, including those on immunosuppressive therapy for autoimmune diseases, transplant recipients, and people with blood cancers.⁸

A consistent and counterintuitive finding across studies is that PJP tends to be more fatal in people who do not have HIV than in those who do. The French data showed hospital mortality of 27% in non-AIDS patients versus 4% in AIDS patients.⁹ A Korean study found 28-day survival rates of roughly 69% in non-HIV patients compared to about 89% in HIV-positive patients, despite the fact that initial clinical features often appeared worse in the HIV group.¹⁰ Part of the explanation is timing: non-HIV patients tend to take longer from symptom onset to diagnosis and treatment, and longer time to treatment worsens outcomes. Another factor is the underlying diseases themselves, since bone marrow transplant recipients and patients on heavy immunosuppression carry additional mortality risk independent of PJP.

Non-HIV PJP also looks different on imaging. HIV-positive patients tend to show the textbook pattern of widespread hazy lung opacities, while non-HIV patients more often have atypical imaging findings, which can delay suspicion of PJP in the first place.¹¹

How PJP Is Diagnosed

Diagnosing PJP involves a combination of imaging, blood tests, and examination of respiratory samples. No single test is perfect, and because P. jirovecii cannot be cultured in a standard lab, clinicians have to rely on indirect and direct detection methods.

CT Imaging

The most common finding on a high-resolution chest CT scan is diffuse ground-glass opacity, a hazy whitening of the lungs that looks like frosted glass. This pattern should raise strong suspicion for PJP in anyone who is immunocompromised.¹² Less commonly, consolidation, nodules, cysts, and even spontaneous pneumothorax can develop.¹³ As already noted, non-HIV patients are more likely to show atypical patterns, which means a CT scan that does not look like “classic PJP” does not rule it out in someone at risk.

Blood Biomarkers

A blood test for beta-D-glucan (BDG), a component of fungal cell walls, has become a widely used screening tool. Meta-analyses have found that its sensitivity for PJP is high, on the order of 91 to 96%, though specificity is lower, around 79 to 84%, since other fungal infections can also elevate it.¹⁴ The sensitivity is somewhat better in HIV-positive patients than in HIV-negative ones, at about 94% versus 86%.¹⁵ A very high BDG level, above 400 pg/mL in one HIV cohort, was highly specific for PJP, while a very low level below 80 pg/mL essentially ruled it out.¹⁶ Results that fall in between are less helpful and usually push clinicians toward more definitive testing.

Microscopy and PCR

The traditional gold standard is direct visualization of the organism in a respiratory sample, usually obtained through bronchoalveolar lavage. Staining methods such as methenamine silver stain or immunofluorescence with monoclonal antibodies can identify the cyst forms under a microscope. In one comparison, immunofluorescence detected P. jirovecii in about 86% of positive samples, while silver stain found it in about 81%.¹⁷

PCR testing has increasingly supplemented or replaced microscopy because it is more sensitive. The challenge with PCR is that it picks up colonization as well as true infection. Quantitative PCR can help here: higher fungal loads in a respiratory sample correlate with actual pneumonia rather than carriage. Studies have proposed cycle-threshold cutoffs, below which the fungal burden is high enough to predict true PJP with a positive predictive value above 85%.¹⁸ Very low-level positive results, conversely, are more likely to represent colonization.¹⁹ In practice, clinicians weigh the PCR result alongside the clinical picture, imaging, and BDG levels rather than treating any single test as definitive.

Treatment With TMP-SMX

The cornerstone of PJP treatment is trimethoprim-sulfamethoxazole, commonly known as TMP-SMX or co-trimoxazole. The standard “conventional dose” for treatment is high, typically 15 to 20 mg/kg per day of the trimethoprim component, given intravenously or orally for 21 days. This dose works well against the infection but causes a lot of side effects, including nausea, kidney problems, low sodium levels, rashes, and drops in blood cell counts.

There has been growing interest in whether lower doses might be just as effective with fewer adverse effects, especially in non-HIV patients. A multicenter retrospective study comparing low-dose to conventional-dose TMP-SMX in non-HIV PJP patients found no significant difference in 30-day or 180-day mortality between the two groups, but the low-dose group experienced substantially fewer side effects, with adverse events occurring in about 30% of patients versus 59% with conventional dosing.²⁰ An earlier observational study similarly explored intermediate and step-down dosing strategies, finding low relapse rates even in patients who switched to lower doses within a few days.²¹ These are not definitive randomized trials, so the optimal dose remains debated, but the trend is toward questioning whether maximal dosing is always necessary.

The Corticosteroid Question

Adding corticosteroids to PJP treatment has been standard practice in HIV-positive patients with moderate-to-severe disease since a landmark trial in 1990 demonstrated that early corticosteroids reduced the risk of respiratory failure and death in AIDS patients with PJP.²² The rationale ties back to the immune-mediated lung injury described earlier: steroids dampen the inflammatory response that contributes to oxygen exchange problems.

Whether this benefit extends to non-HIV patients has remained an open question for decades. A recent multicenter randomized controlled trial specifically tested adjunctive corticosteroids in HIV-negative patients with PJP-related respiratory failure. Mortality at 28 days was lower in the steroid group (about 22%) than in the placebo group (about 32%), but the difference did not reach statistical significance.²³ The trend was encouraging, but the result means clinicians still lack the definitive proof they have for HIV-positive patients. Many still use steroids in severe non-HIV PJP on a case-by-case basis, weighing potential benefit against the risks of further immunosuppression.

When First-Line Treatment Fails

Some patients do not respond to TMP-SMX, and options for second-line therapy are limited and imperfect. In a study of non-HIV patients who needed a switch, only about 57% responded to second-line treatment overall. No specific drug or combination stood out as clearly superior, though the combination of clindamycin plus primaquine had the lowest in-hospital mortality at roughly 22%, significantly lower than other regimens.²⁴ Other second-line options include intravenous pentamidine, atovaquone, and dapsone-based regimens. The evidence base for all of them is thin, consisting mostly of observational data and case series. This is one of the areas where better research is most urgently needed.

Drug Resistance Concerns

Because P. jirovecii cannot be cultured in the lab, studying drug resistance is harder than for bacteria. Researchers instead look for mutations in the gene encoding dihydropteroate synthase (DHPS), the enzyme that sulfa drugs target. Mutations at specific positions in this gene have been found in Pneumocystis samples from around the world, and they are consistently associated with prior use of sulfa drugs for prophylaxis.²⁵ Laboratory work has confirmed that these mutations confer cross-resistance to most sulfa drugs tested, and having both common mutations simultaneously increases resistance further.²⁶

These mutations have been detected across geographic regions, although their prevalence varies.²⁷ Whether DHPS mutations actually translate into treatment failure at the bedside is less clear-cut. Epidemiological studies have linked them to worse outcomes in some settings, but TMP-SMX remains effective for the vast majority of PJP cases. Still, the trend is worth watching, particularly in areas with heavy prophylactic sulfa use.

Preventing PJP With Prophylaxis

For people with HIV, guidelines recommend starting PJP prophylaxis when the CD4 count drops below 200 cells per cubic millimeter, or when oropharyngeal candidiasis is present. A CD4 percentage below 14% is another trigger for prophylaxis in some guidelines.²⁸ The prophylactic drug of choice is the same as the treatment: TMP-SMX, but at much lower doses, often a single-strength tablet daily or a double-strength tablet three times a week. Alternatives for patients who cannot tolerate sulfa drugs include dapsone, atovaquone, and aerosolized pentamidine.

An important practical question for people on antiretroviral therapy is when it is safe to stop prophylaxis. European guidelines have traditionally recommended discontinuation only after the CD4 count rises above 200. U.S. guidelines have taken a slightly more permissive approach, suggesting that secondary prophylaxis (given after a PJP episode to prevent recurrence) can be safely stopped at a CD4 count above 100 if the viral load is fully suppressed. A large European cohort study supports the U.S. position, finding that the rate of recurrent PJP in virally suppressed patients with CD4 counts between 100 and 200 who stopped prophylaxis was below 10 per 1,000 person-years.²⁹

For non-HIV patients, prophylaxis recommendations vary by the underlying condition and the immunosuppressive regimen. Transplant recipients, patients on prolonged high-dose corticosteroids, and those receiving certain chemotherapy protocols are commonly given prophylaxis. The challenge is that there is no single biomarker equivalent to the CD4 count that tells clinicians exactly when a non-HIV patient’s risk is high enough to warrant it, so decisions often depend on institutional protocols and clinical judgment.

PJP in Children and Malnourished Populations

Before the HIV epidemic, PJP was best known as a disease of malnourished and premature infants. In low-resource settings, that association persists. A study from Kampala, Uganda found that P. jirovecii was present in about 17% of children admitted with severe pneumonia, and 60% of those with confirmed PJP were younger than six months.³⁰ Severe protein-calorie malnutrition itself appears to be a host risk factor: decades ago, researchers found Pneumocystis in the lungs of South African children who had died with kwashiorkor, while matched well-nourished children showed no organisms.³¹ These findings serve as a reminder that PJP is not solely a disease of modern immunosuppression; any severe impairment of the immune system, including malnutrition, can set the stage.

Extrapulmonary Disease

In rare cases, P. jirovecii spreads beyond the lungs. Extrapulmonary pneumocystosis has been described in lymph nodes, spleen, liver, bone marrow, eyes, and soft tissues. It occurs almost exclusively in people with profoundly suppressed immunity, particularly those with very advanced HIV. Symptoms depend on which organ is involved and are often nonspecific. A case report described a woman with a CD4 count of just 16 cells per cubic millimeter who developed a paravertebral soft tissue mass that, on biopsy, revealed granulomatous inflammation with the foamy material characteristic of Pneumocystis.³² Patients with extrapulmonary disease frequently do not have concurrent PJP in the lungs, which can make diagnosis especially tricky.³³

Why the Name Keeps Changing

If you have seen this disease referred to as both PCP and PJP, you are not confused: the nomenclature really is that messy. Pneumocystis was originally classified as a protozoan parasite and later reclassified as a fungus based on genetic analysis. The species that infects humans was long called Pneumocystis carinii, giving the pneumonia its abbreviation PCP (Pneumocystis carinii pneumonia). In 2002, the human species was formally renamed Pneumocystis jirovecii in honor of the Czech parasitologist Otto Jírovec, while P. carinii was retained for the species that infects rats.³⁴ The abbreviation PJP (for Pneumocystis jirovecii pneumonia) gradually replaced PCP in medical literature, though many clinicians and older references still use PCP out of habit. Some institutions have tried to compromise by saying PCP stands for “Pneumocystis pneumonia” generically, sidestepping the species question. Whatever you call it, you are talking about the same disease.